Alnylam Pharmaceuticals, Inc.

Arbutus entered into a license agreement with Alnylam that provides Arbutus with royalty entitlements to Alnylam’s global net sales of ONPATTRO, the first FDA approved application of Arbutus’ LNP technology. Under the terms of this license agreement, Arbutus is entitled to tiered royalty payments on global net sales. Arbutus has sold its royalty interest on future global net sales of ONPATTRO to the Ontario Municipal Employees Retirement System (“OMERS”) under a Purchase and Sale Agreement. In addition to the royalty from the Alnylam License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (“Acuitas”). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.